<DOC>
	<DOC>NCT02231125</DOC>
	<brief_summary>-IgA nephropathy is the most common primary glomerular disease in China, Huangkui Capsule is a single medicament of traditional Chinese medicine consists of Abelmoschus manihot and has been widely used to treat kidney disease. The purpose of this study is to evaluate the safety and efficacy of Abelmoschus manihot for treating IgA nephropathy in large scale samples with long time take.</brief_summary>
	<brief_title>Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy</brief_title>
	<detailed_description>The test has not been completed .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis, IGA</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Clinical diagnosed as chronic nephritic syndrome IgA nephropathy diagnosed by kidney biopsy Aged from 18 to 65 years，male or female Blood pressure of ≤140/90mmHg Estimated Glomerular Filtration Rate (eGFR)≥45ml/min/1.73 m2 24hour proteinuria ranged between 0.5g3.0g Obtaining the signed informed consent from patients Secondary IgA nephropathy Be allergic to Huangkui Capsule or Losartan potassium tablet Taken Huangkui Capsule or ACEI or ARB in last 6 weeks Taken the glucocorticoids, immunosuppressants or common threewingnut root and such as drugs with immunosuppressive actions in the last 12 months Blood pressure ＜90/60mmHg Serum potassium level &gt; 5.5mmol / L Serum albumin level &lt;30g / L Lactation, pregnancy or plans pregnancy during the study period Unilateral or bilateral renal artery stenosis Combined with severe primary diseases of heart, brain, liver and hematopoietic system and so on, or other serious diseases which can affect the patient's life Participating in another clinical study in the same period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Abelmoschus manihot</keyword>
	<keyword>IgA Nephropathy</keyword>
	<keyword>proteinuria</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>